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KEYWORDS Summary Stroke is an important complication of sickle cell disease. Approximately twenty-
four percent of patients have a stroke by the age of 45. Blood transfusions decrease stroke risk inTranscranial Doppler;
Stroke;
Sickle cell disease;
Brasilian Guideline
patients deemed at high risk by transcranial Doppler (TCD) by evidence of elevated intracranial
internal carotid or middle cerebral artery velocity. This review describes the practical procedure
of patient evaluation and illustrates, through Brazilian guidelines, the importance of uniform
methodology in a setting with high prevalence of this disease.
© 2012 Elsevier GmbH.
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Open access under CC BY-NC-ND license.Sickle cell disease (SCD) is a genetic disorder caused
by homozygosity for a single -globin gene mutation
(6GAG→GTG), in which glutamic acid has been substi-
tuted for valine at the sixth codon of the -globin chain.
Although the incidence of strokes is higher in patients with
the Hb SS and Hb S/ß0 thalassemia genotype, it should be
noted that strokes also occur in patients with other geno-
types. The clinical course of patients suffering from SCD is
extremely variable and the severity of manifestations rang-
ing from asymptomatic to a very severe course [1]. SCD is
characterized by chronic hemolytic anemia and intermit-
tent vaso-occlusive events. These events result in tissue
ischemia, which leads to acute and chronic pain as well
as damage to any organ in the body. Acute complications
include ischemic and hemorrhagic stroke, acute chest syn-
drome, painful vaso-occlusive crises, splenic sequestration,
aplastic crises, and bacterial sepsis due to hyposplenia.
Chronic morbidities include cerebrovascular disease, pul-
monary hypertension, osteonecrosis, nephropathy and organ
failure [2]. The vaso-occlusive process in SCD is of a com-
plex nature mediated by red cell and leukocyte adhesion,
inﬂammation, oxidative stress, and a hypercoagulable state,
all resulting in endothelial injury and dysfunction [3]. In
addition, by reducing the nitric oxide bioavailability and by
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Open access under CC BY-NC-ND license.amaging the endothelium through catalyzation of oxida-
ive reactions in endothelial cells, chronic hemolysis leads
o vascular complications [4—6]. Although stroke can occur
t any age, the most vulnerable group for ischemic stroke
s between the age of 2 and 20 years (0.30—0.75 acute
vents/100 patients/year) [7]. Stenotic lesions involve pri-
arily large vessels in the intracranial internal carotid,
iddle, and anterior cerebral circulation and can progress
or months and even years before symptoms develop [8,9].
here is also evidence that sickle cell anemia (SCA) and
ther chronic hemolytic anemia are characterized by a
ypercoagulable state with an increased generation of
hrombin and ﬁbrin as well as platelet activation thus
ncreasing the risk for thromboembolic complications [10].
Transfusion therapy has been shown to prevent the devel-
pment of stroke, but unfortunately this procedure has
mportant side effects such as iron overload and alloimmu-
ization. Identifying these patients at high risk is crucial in
he selection of patients that would most beneﬁt from this
ntervention. Based on two large studies [11,12] we can now
etect patients developing cerebral vasculopathy using tran-
cranial Doppler ultrasonography (TCD). Adams et al. ﬁrst
howed the effectiveness of nonimaging Doppler in screen-
ng for cerebrovascular disease in SCD. Using the transtem-
oral and suboccipital approach, they screened 190 asymp-
omatic sickle cell patients and found in the clinical follow-
p that a time-averaged mean of the maximum velocity
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Table 1 Recommendations for the frequency of TCD according to the result of the examination.
Result of TCD CBFV (cm/s) Frequency of exam
Absence of window — Use other image resource to analyze the cerebrovascular event
Technical difﬁculty due to lack
of cooperation
— Repeat every three months. We recommend evaluation by
another examiner
Low CBFV 70 Repeat after 1 month
Normal CBFV <170 Repeat annually
Low conditional * Between 170 and 184 Repeat at three-month intervals. In the case of normal
subsequent results, we should adopt the normal conduct for
the group
High conditional * Between 185 and 199 Repeat after 1 month. In cases of unchanged examinations, it
is recommended to repeat every three months. In cases of two
consecutive abnormal results, it is recommended to discuss
the risk of strokes and consider a chronic transfusion regimen
Abnormal
Between 200 and 219 Repeat after 1 month. If the value remains ≥200, it is
recommended to discuss the risk of strokes and consider
chronic transfusion regimen. If the result decreases to
170—199, it is recommended to repeat it one month if high
conditional (between 185 and 199); or 6 months if conditional
low (between 170 and 184). If the result is normalized (<170),
it is recommended to repeat in 1 year
More than 220 Discuss imminent risk of strokes and consider chronic
transfusion regime
TCD= transcranial Doppler and CBFV = cerebral blood ﬂow velocity.
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n* TCD denotes transcranial Doppler and CBFV cerebral blood ﬂo
TAMMX) in the middle cerebral artery (MCA) > 170 cm/s was
n indicator of a patient at risk for development of stroke
13]. They then compared TCD to cerebral angiography in
3 neurologically symptomatic patients and identiﬁed ﬁve
riteria for cerebrovascular disease:
. TAMMX of 190 cm/s
. Low velocity in the MCA <70 cm/s
. Right/Left MCA ratio <0.5
. Anterior cerebral artery (ACA)/MCA ratio >1.2 on the
same side
. Inability to detect an MCA in the presence of a demon-
strated ultrasound window
A follow-up of neurologically symptomatic and asymp-
omatic sickle cell patients presented other factors that
ere signiﬁcant in the identiﬁcation of patients at risk:
elocity in the ophthalmic artery > velocity of the ipsilat-
ral MCA, maximum velocity in the posterior cerebral (PCA),
ertebral, or basilar arteries >maximum velocity in the MCA,
urbulence, PCA visualized without the MCA [13].
The STOP (Stroke Prevention Trial in Sickle Cell Anemia)
tudy conﬁrmed that TCD could reliably identify those at the
ighest risk for stroke [12]. STOP screened more than 2000
ickle cell children using the nonimaging TCD technique for
igns of cerebrovascular disease. TCD results were classiﬁed
o indicate degree of risk for stroke as normal, conditional,
bnormal, or inadequate. In this series, Adams demon-
trated that children with TAMMX of >200 cm/s in the distal
nternal carotid artery or proximal MCA had a stroke risk that
as 10—20 times that of the general sickle cell population of
he same age. Children with a TAMMX of the MCA >200 cm/s
v
t
p
tocity.
n two separate readings were randomly assigned to two
roups. Sixty-seven children received standard support-
ve care with symptomatic treatment. Sixty-three children
eceived periodic blood transfusions to maintain hemoglobin
levels at 30%or less. After 1 year, ten children in the stan-
ard care group had a stroke, while only one child in the
ransfusion group had a stroke. This presents a 90% rela-
ive decline in stroke rate. We must emphasize that the
TOP velocity criteria apply only to children with SCD who
ave not had a stroke. Those with abnormal velocity should
ndergo repeated screening within the next few weeks and if
he second study is also abnormal should be offered trans-
usion therapy. Those with conditional velocity should be
escreened within 3—6 months, while those with normal
tudies can be rescreened yearly [15]. Based on these stud-
es and considering that SCD is the most common monogenic
ereditary disease in Brazil, occurring predominantly among
frican descendents, we have decided to publish Brazilian
uidelines for transcranial Doppler in children and adoles-
ents with sickle cell disease with the intent to expand
ealth policy and to contribute in reducing morbidity and
ortality resulting from this pathology in our setting [16]
Table 1).
For this review we will consider only the nonimaging
ulsed Doppler TCD technique used in the STOP trial [12].
e do not currently recommend that centers use an imaging
CD. The use of different machines and different US tech-
iques could result in velocities of up to 10% lower than STOP
elocities and the angle correction could result in veloci-
ies higher than those obtained using the STOP protocol. At
resent, there is no consensus regarding the actual velocity
hat should be considered as a cutoff value for TCD imaging.
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The most important methodology: vessels should be
examined carefully by obtaining sample volumes throughout
the MCA at intervals of 2mm while gain settings should be
optimized to measure the peak-systolic velocity. The angle
of insonation is assumed to be 0◦. The examination should
include manual measurement of the velocity to conﬁrm the
ﬁndings. Blood ﬂow velocities from the major cerebral arter-
ies are measured through transtemporal and transforaminal
windows with the use of a 2-MHz probe. The mean time-
averaged maximum velocity (TAMMX) of the terminal portion
of the internal carotid artery (ICA), M1 segment of the mid-
dle cerebral artery (MCA), A1 of the anterior cerebral artery
(ACA), P1 or P2 of the posterior cerebral artery (PCA), V4
segments of the vertebral arteries bilaterally, and basilar
artery (BA) were measured in the STOP study for at least
3 complete cardiac cycles. Wave spectral information was
not used and the submandibular and transorbital windows
were not evaluated. It should be noted that very low speeds
(<70 cm/s) may be indicative of severe stenosis. Although a
complete exam is recommended when possible, currently,
the terminal ICA and proximal MCA are the most essential
elements for analysis. All TCD studies should be classiﬁed
based on the highest time-averaged mean blood ﬂow veloc-
ity in the ICA or MCA based on STOP criteria [12]. The
cutoff values and considerations about the re-examination
are shown in Table 1 [16].
The procedure, as well as the need to remain awake and
cooperative during the examination, should be explained to
the patient. Some centers allow children to watch a movie
during the examination. When the patient becomes sleepy,
the CO2 levels increase which elevates the mean ﬂow veloc-
ity and could give a false-positive result. Hypoxia, fever,
hypoglycemia and worsening anemia can also increase cere-
bral blood ﬂow and ﬂow velocity. Thus, if a child has sickle
chest syndrome, sequestration, and hemolytic crisis, TCD
velocity will appear higher than the true baseline. Although
it is tempting to perform TCD examinations while a patient
is in the hospital for a medical illness, the results may not be
valid if velocities drop to an abnormal or conditional range.
These results, therefore, should not be used to determine
stroke risk, and repeated examinations should be performed
when the patient is stable. It is essential to use educational
intervention to target parents and caregivers as well as chil-
dren about the importance of conducting systematic TCD
examinations.
The use of criteria other than ICA/MCA was analyzed in
some studies; however, there is no consensus that allows
us to recommend chronic transfusion. Nevertheless, we
suggest attentiveness to changes in other arteries and a
thorough understanding of ‘‘individual risk’’ thereby reduc-
ing the need for numerous exam repetitions. Children with
abnormal ICA/MCA velocities and elevated anterior cere-
bral artery (ACA) velocities presented a risk of stroke more
than twice that of those with abnormal ICA/MCA but nor-
mal ACA velocity [19]. There are similar ﬁndings with the
basilar artery, vertebral, PCA and OA when compared with
the ICA/MCA, however, the recommendations must be more
uniform.Although in themajority of cases, velocities could go back
to a normal range (MCA TAMMX< 170 cm/s) after a period of
30 months or longer, discontinuation can result in a high
rate of reversion to abnormal blood-ﬂow velocities on the267
CD or even in stroke. The STOP II study concluded that
e must maintain chronic transfusion indeﬁnitely [17,18].
ther treatment regimens are now being tested [20].
TCD screening rates in children with SCD have increased
fter the publication of the STOP trial, andmedical providers
ay be targeting those children at the highest stroke risk.
rospective follow-up of a larger sample will be required
o assess the impact of this screening on stroke rates. TCD
creening itself only stratiﬁes stroke risk, but does not
revent stroke; stroke prevention depends on the imple-
entation of chronic transfusion therapy. However, access
o vascular laboratories appears to be a barrier to the
mplementation of this highly effective stroke prevention
trategy, even among children with comprehensive health
nsurance. The main problems are difﬁculties in perform-
ng the examination, differences in imaging and nonimaging
echniques, and interpretation of guidelines.
The identiﬁcation of sickle cell vasculopathy by MRI, MRA,
nd MR diffusion imaging has increased our understanding
f sickle cell lesions. Silent infarction incidence could be as
igh as 17% and carries a risk of future infarctions as well
21]. The etiology of silent infarctions, however, remains
nresolved, and the implications for preventive therapy
ontinue to be studied. At present, we should attempt to
ncrease the availability of TCD screening by physician train-
ng and TCD machine access in the locations of disease
revalence. We have employed a task force in Brazil through
ublication of guidelines and establishment of medical ser-
ices training in order to improve the performance of TCD
16].
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